In Asian subjects in the EGFR-TKI group, the OR of ILD incidence at any grade with VEGF/VEGFR inhibitors was 0.50 (95% CI, 0.29–0.86; p = 0.01), which indicated a significantly lower incidence than that without VEGF/VEGFR inhibitors (Figure 3C). This evidence concerns the gene EGFR and interstitial lung disease.